Table 2.
Study | Cell Line | Concentration | Algal Species and Fucoidan Purified | Cell Signaling Activity | Reference |
---|---|---|---|---|---|
Fucoidan altered the immunomodulatory markers and DCs phenotype | Human monocyte-derived dendritic cells (DCs) |
100 μg/mL fucoidan | Standard fucoidan-Fucoidan purified from Fucus vesiculosus was purchased | Fucoidan elevated the expression of HLA-DR and co-stimulatory molecules of DCs, induces their Th1-promoting tumor necrosis factor α (TNF-α) and interleukin-12 (IL-12) secretion. This fucoidan is suggested to be used in DC-based vaccines for cancer immunotherapy. | Yang et al. (2008) [72] |
Fucoidan express immunostimulating and DC maturing potential | Bone marrow-derived dendritic cells (DCs) |
50 μg/mL | Standard fucoidan-Fucoidan purified from Fucus vesiculosus was purchased | The production of IL-12, TNF-α, major histocompatibility complex class I, II, CD54, and CD86 were promoted by fucoidan. Further fucoidan treated DCs expressed p65 (NF-κB) nuclear translocation. | Kim et al. (2008) [73] |
Effect of fucoidan on spleen DCs and in vivo | Spleen dendritic cells (DCs) | C57BL/6 mice were treated with 10 mg/kg fucoidan for 24 h | Standard fucoidan-Fucoidan purified from Fucus vesiculosus was purchased | Systemic administration of fucoidan induced up-regulation of CD40, CD80 and CD86 expression and production of IL-6, IL-12 and TNF-a in spleen cDCs. Fucoidan also promoted the generation of IFN-c-producing Th1 and Tc1 cells in an IL-12-dependent manner. Moreover, fucoidan enhanced OVA-induced up-regulation of MHC class I and II on spleen cDCs and strongly prompted the proliferation of OVA-specific CD4 and CD8 T cells. The study reveals the potential of fucoidan to function as an adjuvant to induce Th1 immune response. Further, fucoidan promote CTL activation. Suggested to be useful in tumor vaccine development. | Jin et al. (2014) [74] |
Immunomodulating potential of fucoidans on murine macrophages and splenocytes | RAW 264.7 cells, peritoneal macrophages and normal splenocytes | 50–300 μg/mL | Anion exchange column purified fucoidan from Undaria pinnatifida | Fucoidan induced TNF-α expression from both types of macrophages. The TNF-α-inducing activity of UP-F was higher than that of FV-F. The chemokine expression (RANTES and MIP-1α) was also promoted in RAW 264.7 macrophages. The IL-6 including chemokines were significantly improved in UPF treated splenocytes. | Yoo et al. (2007) [75] |
Macrophages and glial cells were examined for immune related properties against IFN-γ stimulation and fucoidan treatment | Glia (C6, BV-2) and macrophages (RAW 264.7, peritoneal primary cells) | 50 μg/mL | Standard fucoidan-Fucoidan purified from Fucus vesiculosus was purchased | In glial cells IFN-γ induced inflammation was suppressed by fucoidan via JAK/STAT/IRF-1 and p-p38. The signaling positively regulated IFN-g-induced iNOS, which were inhibited by fucoidan. Contrastingly, in RAW macrophages, fucoidan promoted immune responses induced via IFN-γ. Confirmed the dual regulation of p38 in BV-2 microglia and primary peritoneal macrophages. | Do et al. (2010) [76] |
In vivo viral replication and host immune defense system were assessed against fucoidan treatment | Macrophages were collected from BALB/c mice | 10 μg/mL | Fucoidan prepared from Undaria pinnatifida | Fucoidan oral administration protected mice from infection with HSV-1. CTL activity of HSV-1 mice was enhanced by fucoidan. Phagocytic activity of macrophages and B cell blastogenesis in vitro was significantly stimulated by the fucoidan, while no significant change in the release of NO2− by macrophages was observed. | Hayashi et al. (2008) [3] |
Immune boosting properties of fucoidan from Nizamuddinia zanardinii | RAW 264.7 macrophage cell | 10, 25 and 50 μg/mL | Anion exchange column purified fucoidan. | The active fraction (F3) promoted the secretion of NO, TNF-α, IL-1β, IL-6 in RAW 264.7 macrophages. Further NK cells were activated to release TNF-α, IFN-γ, granzyme-B, perforin, NKG2D and FasL. The activity was mediated through NF-κB and MAPK pathways. | Tabarsa et al. (2020) [100] |